Portal de investigação
Impact of disease duration on proteomic bioprofile and prognosis in rheumatoid arthritis patients
Autores da FMUP
Participantes de fora da FMUP
- Brandao, M
- Fonseca, T
- Costa, RQ
- Oliveira, JC
- Carvalho, HC
- Rodrigues, P
- Zannad, F
- Rossignol, P
- Ferreira, MB
Unidades de investigação
Abstract
Objective Cardiovascular disease worsens the prognosis of rheumatoid arthritis (RA) and vice-versa. Inflammation may be a common pathway for both conditions. It is expected that a longer RA duration leads to a greater inflammatory cumulative exposure burden; however, studies on the association between RA disease duration and outcomes are scarce. Our aim is to compare the characteristics, biomarker expression and outcomes according to the duration of RA. Methods Prospective cohort study including 399 RA patients, with detailed clinical, echocardiographic, and proteomic phenotyping that were compared across tertiles of RA disease duration. Cox proportional models were used to study the association of disease duration with cardiovascular outcomes. Results RA duration tertiles were: tertile 1 with median of 3.2; tertile 2 with median of 8.8; and tertile 3 with median of 21.8 years. Compared to tertile 1, patients in tertile 3 were older, had more erosive disease, more frequent echocardio-graphic alterations, lower haemoglobin and walked a shorter distance on the 6MWT. Natriuretic peptides, cathepsin L1, galectin 9, matrix metalloproteinase-12, adrenomedullin and tumour necrosis factor receptor 11A were higher in patients with longer disease duration. Compared to patients in tertile 1, those in tertile 3 had higher risk of a subsequent cardiovascular hospitalisation or cardiovascular death (HR 2.71, 95%CI 1.06-6.92, p=0.04). Conclusion RA patients with longer disease duration had more organ damage and worse outcomes than those with shorter disease duration. Biomarker expression suggested that patients with longer RA duration had activation of pathways related to inflammation, extracellular matrix organisation, fibrosis and congestion.
Dados da publicação
- ISSN/ISSNe:
- 0392-856X, 1593-098X
- Tipo:
- Article
- Páginas:
- 2162-2166
- Link para outro recurso:
- www.scopus.com
Clinical and Experimental Rheumatology Clinical and Experimental Rheumatology S.A.S.
Citações Recebidas na Web of Science: 1
Citações Recebidas na Scopus: 4
Documentos
- Não há documentos
Filiações
Keywords
- rheumatoid arthritis; disease duration; prognosis; biomarkers
Campos de estudo
Financiamento
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Initiation of ARNi and SGLT2i in Patients With HFrEF: Randomized Open-label Trial (INITIATE-HFrEF) -NCT05989503
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (INITIATE-HFrEF) . Novartis . 2023
Citar a publicação
Brandao M,Fonseca T,Costa RQ,Oliveira JC,Carvalho HC,Rodrigues P,Zannad F,Rossignol P,Ferreira MB,Ferreira JP. Impact of disease duration on proteomic bioprofile and prognosis in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 2023. 41. (11):p. 2162-2166. IF:3,700. (3).
